arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

InMed Pharmaceuticals Inc.

INM

$1.47 ▲ +0.01 (+1.03%) at close

7 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

InMed Pharmaceuticals Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.4M

Dividend Yield —

Revenue Growth 7.5% ↘

Op. Margin None

ROIC None

FCF / Share $-7.96 ↗

Trailing P/E —

Price / Book 0.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$4.94M

↑ +7.5% —

Net Income Profit after all expenses

$-8.16M

↓ -6.3% —

FCF / Share Free cash flow per share

$-7.96

↑ +56.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↑

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗	FY 2019 Jun 30, 2019 10-K ↗
Revenue Growth YoY (%)	7.5% Fair ↓ Fair Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-6%)	11.2% Good ↓ Good Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+40%)	279.6% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3395%)	-42.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-635%)	—	—	—
EPS Growth YoY (%)	58.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-519.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	90.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	12.6% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-6.3% Weak ↑ Weak Improving Year-over-year change in net income	3.4% Caution ↑ Caution Improving Year-over-year change in net income	57.3% Excellent ↑ Excellent Improving Year-over-year change in net income	-82.3% Weak Weak Year-over-year change in net income	-14.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	56.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-503.9% Weak ↓ Weak Declining Year-over-year change in free cash flow	89.1% Excellent Excellent Year-over-year change in free cash flow	23.5% Good Good Year-over-year change in free cash flow	—	—	—
Revenue CAGR 3Y (%)	65.5% Excellent Excellent Compound annual revenue growth over 3 years	34.2% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗	FY 2019 Jun 30, 2019 10-K ↗
Operating Margin (%) (%)	—	—	-192.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1381%)	—	—	—	—
Effective Tax Rate (%) (%)	—	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—
Profit Margin (%) (%)	-165.1% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1476%)	-166.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1491%)	-192.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1701%)	—	—	—	—
FCF Margin (%) (%)	-157.1% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-152.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-180.0% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗	FY 2019 Jun 30, 2019 10-K ↗
Return on Invested Capital (%)	—	—	-65.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-161.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-109.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	—	—	-56.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-145.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-104.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-60.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-505%)	-83.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-656%)	-65.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-538%)	-204.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1466%)	-138.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1022%)	-152.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1114%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗	FY 2019 Jun 30, 2019 10-K ↗
Interest Coverage (x)	—	—	—	—	-28.31x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-11.08M	$-6.57M	$-8.91M	$-6.18M	$-7.36M	$-5.81M	$-9.84M

📊 What does each share earn? 6 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗	FY 2019 Jun 30, 2019 10-K ↗
Revenue per Share (USD)	$5.06	$12.07	$1.69	$1.94	$7.08	—	—
Basic EPS, GAAP (USD)	$-8.36	$-20.14	$-3.25	$-33.17	$-37.96	—	—
Free Cash Flow per Share (USD)	$-7.96	$-18.36	$-3.04	$-27.86	$-36.43	—	—
Book Value per Share (USD)	$6.71	$20.65	$3.63	$13.95	$22.91	$1.13	—
Tangible Book Value per Share (USD)	$5.90	$16.65	$3.05	$10.71	$19.61	$0.92	—
Basic Weighted Avg Shares (shares)	975,985	381,053	2.45M	560,829	268,793	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗	FY 2019 Jun 30, 2019 10-K ↗
Working Capital (USD)	$11.03M	$6.72M	$9.33M	$6.28M	$6.16M	$4.64M	—
Total Equity (USD)	$13.43M	$9.21M	$12.09M	$9.08M	$7.38M	$5.88M	$14.24M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗	FY 2019 Jun 30, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$4.94M	$4.60M	$4.14M	$1.09M	$1.90M	—	—
Depreciation Expense (USD)	$212.84K	$219.60K	$202.25K	$185.66K	$120.87K	$112.43K	—
Net Income, GAAP (USD)	$-8.16M	$-7.68M	$-7.95M	$-18.60M	$-10.20M	$-8.94M	—
Operating Cash Flow (USD)	$-7.77M	$-6.99M	$-7.28M	$-15.58M	$-9.79M	$-7.37M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 28 quarters

InMed Pharmaceuticals Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare INM with peers